The company has not filed an annual or quarterly report since its Q2 FY2020 10-Q, filed Aug 5, 2020. Its latest SEC filing is a SC 13G/A from Feb 16, 2021.
10-Q for Q2 FY2020, filed Aug 5, 2020
The sections below describe the company as of the FY2019 annual report.
Develops antibody-based medicines that target cancer for patients with cancer.
10-K for FY2019, filed Feb 27, 2020
The company earns an upfront license payment from Everest, with potential further milestone payments and royalties on net sales. Janssen pays service fees for product-detailing work when sales targets are met.
10-K for FY2019, filed Feb 27, 2020On April 29, 2019, we entered into a license agreement (the "License Agreement") with Everest Medicines II Limited, a China limited company…View ↗
License Agreement also contains additional development milestone payments in a total amount of up to $180.0 million based upon the…View ↗
On April 5, 2019, the Company entered into a promotion agreement (the "Promotion Agreement") with Janssen Biotech Inc., ("Janssen")…View ↗
$295K
10-K for FY2019, filed Feb 28, 2020
$295K ↗
The company contracts with Everest for a license and with Janssen for product-detailing services; Janssen's product is promoted to oncologists and other targeted U.S. health care providers.
10-K for FY2019, filed Feb 27, 2020On April 29, 2019, we entered into a license agreement (the “License Agreement”) with Everest Medicines II Limited, a China limited company…View ↗
On April 5, 2019, the Company entered into a promotion agreement (the “Promotion Agreement”) with Janssen Biotech Inc., ("Janssen")…View ↗
In April 2019, we entered into the Promotion Agreement with Janssen pursuant to which we will provide non-exclusive product detailing…View ↗
No. It lost $357.2M in FY2019.
10-K for FY2019, filed Feb 28, 2020
−$324.8MView ↗
10-K for FY2019, filed Feb 28, 2020
−$357.2MView ↗
10-K for FY2019, filed Feb 28, 2020
−$229.3MView ↗
10-Q for Q2 FY2020, filed Aug 6, 2020
−$66.5MView ↗
8-K, filed Oct 23, 2020
Following the consummation of the Offer, the remaining conditions to the Merger set forth in the Merger Agreement were satisfied or waived…View ↗
Shrank. Revenue fell 95% in 4 years, from $5.7M in FY2014 to $295K in FY2019, about 52% a year.
Narrower disease focus
The older report described antibody candidates for cancer, autoimmune disorders and other serious diseases; the latest centers the business on cancer treatments, with sacituzumab govitecan as its lead candidate.
10-K for FY2016, filed Aug 18, 2016 10-K for FY2019, filed Feb 27, 2020Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of…View ↗
Loading...
